CA2335134A1 - Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty - Google Patents

Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty Download PDF

Info

Publication number
CA2335134A1
CA2335134A1 CA002335134A CA2335134A CA2335134A1 CA 2335134 A1 CA2335134 A1 CA 2335134A1 CA 002335134 A CA002335134 A CA 002335134A CA 2335134 A CA2335134 A CA 2335134A CA 2335134 A1 CA2335134 A1 CA 2335134A1
Authority
CA
Canada
Prior art keywords
bone
phenyl
oxo
compound
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002335134A
Other languages
English (en)
French (fr)
Inventor
Hua Zhu Ke
Mei Li
David Duane Thompson
Lydia Codetta Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2335134A1 publication Critical patent/CA2335134A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002335134A 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty Abandoned CA2335134A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16
US60/089,469 1998-06-16
PCT/IB1999/001117 WO1999065486A1 (en) 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
CA2335134A1 true CA2335134A1 (en) 1999-12-23

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002335134A Abandoned CA2335134A1 (en) 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Country Status (30)

Country Link
EP (1) EP1087764A1 (de)
JP (1) JP2002518326A (de)
KR (1) KR20010052852A (de)
CN (1) CN1301160A (de)
AP (1) AP9901582A0 (de)
AR (1) AR018869A1 (de)
AU (1) AU4054799A (de)
BG (1) BG105041A (de)
BR (1) BR9911324A (de)
CA (1) CA2335134A1 (de)
CO (1) CO5070587A1 (de)
EA (1) EA200001186A1 (de)
GT (1) GT199900087A (de)
HN (1) HN1999000097A (de)
HR (1) HRP20000859A2 (de)
HU (1) HUP0102505A3 (de)
ID (1) ID27599A (de)
IL (1) IL138630A0 (de)
IS (1) IS5691A (de)
MA (1) MA26652A1 (de)
NO (1) NO20006312L (de)
OA (1) OA11505A (de)
PA (1) PA8475901A1 (de)
PE (1) PE20000646A1 (de)
PL (1) PL344981A1 (de)
SK (1) SK18912000A3 (de)
TN (1) TNSN99124A1 (de)
TR (1) TR200003544T2 (de)
WO (1) WO1999065486A1 (de)
ZA (1) ZA993975B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
ATE346159T1 (de) 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
AU4054799A (en) 2000-01-05
HRP20000859A2 (en) 2001-04-30
HUP0102505A3 (en) 2002-12-28
EP1087764A1 (de) 2001-04-04
MA26652A1 (fr) 2004-12-20
CN1301160A (zh) 2001-06-27
BG105041A (en) 2001-08-31
PE20000646A1 (es) 2000-08-05
CO5070587A1 (es) 2001-08-28
TNSN99124A1 (fr) 2005-11-10
SK18912000A3 (sk) 2001-10-08
BR9911324A (pt) 2001-04-03
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
AR018869A1 (es) 2001-12-12
EA200001186A1 (ru) 2001-06-25
AP9901582A0 (en) 1999-06-30
NO20006312D0 (no) 2000-12-12
ZA993975B (en) 2000-12-15
OA11505A (en) 2004-05-07
GT199900087A (es) 2000-12-07
IS5691A (is) 2000-10-27
WO1999065486A1 (en) 1999-12-23
HN1999000097A (es) 1999-11-03
JP2002518326A (ja) 2002-06-25
KR20010052852A (ko) 2001-06-25
TR200003544T2 (tr) 2001-04-20
PL344981A1 (en) 2001-11-19
NO20006312L (no) 2000-12-12
PA8475901A1 (es) 2000-05-24
ID27599A (id) 2001-04-12

Similar Documents

Publication Publication Date Title
US6132774A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
CA2335134A1 (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
US20020002137A1 (en) Combination of growth hormone secretagogues and antidepressants
WO1999065488A1 (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
US20020151551A1 (en) Use of growth hormone secretagogues in conjunction with physical exercise cross reference to related application
EP0966968B1 (de) Kombinationstherapeutika, enthaltend einen selektiven Östrogenrezeptormodulator und Prostaglandin E2
MXPA00012727A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
CZ20004679A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
US20030199514A1 (en) Methods for improving efficacy of treatment with growth hormone secretagogues
MXPA00012628A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
CZ20004680A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012728A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
Sack Fighting the fracture cascade: evaluation and management of osteoporotic fractures
MXPA99005564A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
JPH10203995A (ja) 抗骨粗鬆症剤
XU et al. Recent advances in pharmacologic prevention and treatment of osteoporosis
CZ20004678A3 (cs) Terapeutické kombinace obsahující selektivní modulátor receptorů estrogenů a hormon příštítných tělísek

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued